Zylacta Overview

  • Founded
  • 2004
  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Latest Deal Amount
  • $254K
Latest Deal Amount
  • Investors
  • 2

Zylacta General Information


Operator of a biotechnology company intended to develop small molecule therapeutics. The company's biotechnology process offers therapeutics based on bacterial cell wall peptidoglycan for immunotherapy and also offers methods to develop these hits into drugs via a gene-based technology, enabling clients to get expertise in genomics of bacterial peptidoglycan synthesis, maturation and shedding.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 7965 Cessna Avenue
  • Gaithersburg, MD 20879
  • United States
+1 (410) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Zylacta Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator 21-Feb-2008 $254K 00000 Completed Generating Revenue
2. Early Stage VC 03-Nov-2006 00000 00000 Completed Startup
1. Grant 26-Sep-2006 $75K Completed Startup
To view Zylacta’s complete valuation and funding history, request access »

Zylacta Executive Team (3)

Name Title Board Seat Contact Info
Robert Shalwitz MD Co-Founder & President
Vladimir Slesarev Ph.D Co-Founder & Chief Medical Officer
To view Zylacta’s complete executive team members history, request access »

Zylacta Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Maryland Industrial Partnerships Other 000 0000 000000 0
TEDCO Venture Capital Minority 000 0000 000000 0
To view Zylacta’s complete investors history, request access »